# Enclomiphene Dosage Protocol Guide: SERM Research (2026)
> Research Use Only (RUO) Disclaimer: Enclomiphene (as a standalone compound) does not have full FDA approval for general use as of 2026, though NDA applications have been submitted by Repros Therapeutics. Racemic clomiphene citrate (which contains the enclomiphene isomer) is FDA-approved for ovulation induction. All information below regarding enclomiphene as a research tool is intended for scientific research purposes. Consult a licensed healthcare professional for any therapeutic needs.
What Is Enclomiphene?
Enclomiphene (INN: enclomifene; formerly designated trans-clomiphene or (E)-clomiphene) is the trans-isomer of clomiphene — a selective estrogen receptor modulator (SERM) that was first synthesized at William S. Merrell Company in the early 1960s. Commercial clomiphene citrate (Clomid, Serophene) is a racemic mixture of two geometric isomers:
- •Enclomiphene (trans-isomer, ~38% of mixture): The pharmacologically active isomer for HPG axis stimulation; rapidly metabolized with a shorter half-life (~10 hours)
- •Zuclomiphene (cis-isomer, ~62% of mixture): The antagonist-dominant isomer; accumulates due to long half-life (~30 days), potentially causing estrogen-agonist effects in some tissues (visual disturbances, mood effects) with chronic use
The key insight driving enclomiphene research: by isolating the trans-isomer, researchers can study HPG axis stimulation without the long-accumulating zuclomiphene interference.
Mechanism of Action: HPG Axis Stimulation
Enclomiphene is a competitive estrogen receptor (ER) antagonist at hypothalamic estrogen receptors. Its mechanism for stimulating testosterone production is indirect but well-characterized:
1. Hypothalamic ER blockade: Enclomiphene occupies estrogen receptors in the hypothalamus, blocking estradiol's negative feedback signal
2. Increased GnRH pulse frequency: Without estradiol feedback, the hypothalamus increases GnRH (gonadotropin-releasing hormone) pulse frequency
3. Pituitary LH/FSH release: Increased GnRH drives the pituitary to release more LH (luteinizing hormone) and FSH (follicle-stimulating hormone)
4. Testicular stimulation: LH stimulates Leydig cells in the testes to produce testosterone; FSH supports spermatogenesis and Sertoli cell function
5. Result: Elevated endogenous testosterone WITHOUT suppressing the HPG axis (unlike exogenous testosterone)
This mechanism distinguishes enclomiphene from testosterone replacement therapy (TRT):
- •TRT: Exogenous testosterone; suppresses HPG axis via negative feedback; reduces LH/FSH to near-zero; impairs spermatogenesis
- •Enclomiphene: HPG axis stimulant; elevated LH, FSH, and testosterone simultaneously; preserves or improves spermatogenesis
Clinical Development History
Repros Therapeutics developed enclomiphene (brand name Androxal in their NDA submissions) specifically for secondary hypogonadism — a form of low testosterone caused by HPG axis dysfunction rather than primary testicular failure.
Key clinical milestones:
- •Phase III SERVEIL trials: Demonstrated statistically significant testosterone restoration (>300 ng/dL) in men with secondary hypogonadism
- •Comparison with testosterone gel: Enclomiphene matched testosterone normalization while maintaining spermatogenesis (testosterone gel caused azoospermia in a significant proportion of subjects)
- •FDA rejection (2015): The FDA rejected the NDA citing the need for additional long-term safety data — not due to safety signals, but due to the unprecedented clinical profile
- •Ongoing development: Enclomiphene has been subsequently studied in fertility contexts and as an off-label research tool for HPG axis restoration after anabolic steroid use
Pharmacokinetics
| Parameter | Enclomiphene | Zuclomiphene (for comparison) |
|---|---|---|
| Plasma half-life | ~10 hours | ~30 days |
| Accumulation | Minimal | Significant with chronic dosing |
| Time to steady state | 2–3 days | Weeks |
| Tissue distribution | Moderate | High (long-term accumulation in tissues) |
| Primary metabolism | Hepatic CYP3A4 | Hepatic |
Enclomiphene's shorter half-life means:
- •Faster onset of HPG axis stimulation
- •Rapid washout when discontinued (HPG axis returns to baseline within days)
- •No long-term accumulation effects seen with racemic clomiphene citrate chronic use
Dosage Protocols in Research Models
Published Clinical Dosing
Phase II/III clinical trials used the following dosing schema:
- •12.5 mg/day: Lower-range dose; effective in many subjects; fewer side effects
- •25 mg/day: Standard dose in most Phase III protocols; effective testosterone normalization in majority of subjects with secondary hypogonadism
Research Dosing Reference
| Research Application | Dose | Frequency | Duration |
|---|---|---|---|
| HPG axis baseline characterization | 12.5 mg/day | Daily (oral) | 4–12 weeks |
| Secondary hypogonadism model | 25 mg/day | Daily (oral) | 12–26 weeks |
| Post-cycle restoration research | 25–50 mg/day | Daily (oral) | 4–8 weeks |
| Fertility/spermatogenesis research | 12.5–25 mg/day | Daily (oral) | 12–26 weeks |
Comparison with Clomiphene Citrate (Racemic) Dosing
Researchers migrating from racemic clomiphene citrate protocols should note:
- •Enclomiphene 25 mg is roughly bioequivalent to clomiphene citrate 50 mg in terms of HPG axis stimulation (accounting for the isomer ratio)
- •Enclomiphene produces less visual disturbance and mood-related side effects due to absence of accumulating zuclomiphene
Post-Cycle Restoration Research (HPG Axis Recovery)
One of the most studied applications of enclomiphene in the research community is HPG axis restoration following exogenous androgen use (anabolic steroid research protocols). Exogenous androgens suppress the HPG axis via feedback inhibition at the hypothalamus and pituitary. After discontinuation, axis recovery can take weeks to months.
Enclomiphene for HPG axis restoration:
- •Blocks hypothalamic ER, removing suppressive estrogen/estrogen-like feedback
- •Drives LH/FSH release → stimulates endogenous testosterone production
- •Can accelerate HPG axis recovery compared to no intervention
Published data from clomiphene-based restoration protocols (applicable to enclomiphene given shared mechanism):
- •LH typically normalizes within 1–2 weeks of SERM initiation
- •Testosterone normalization follows within 2–4 weeks
- •Spermatogenesis recovery is slower (3–6 months in most cases, regardless of SERM use)
HPG Axis Monitoring Parameters
Research protocols studying enclomiphene's HPG axis effects require:
- •LH (Luteinizing Hormone): Primary upstream endpoint; should increase within 48–72 hours of enclomiphene initiation
- •FSH (Follicle-Stimulating Hormone): Elevated with LH; important for spermatogenesis research
- •Total Testosterone: Key downstream endpoint; drawn at baseline, 2 weeks, 4 weeks, and monthly thereafter
- •Free Testosterone and SHBG: Enclomiphene can modestly affect SHBG; free testosterone provides a more complete picture
- •Estradiol (E2): Monitoring required — enclomiphene's ER antagonism at the hypothalamus doesn't fully block peripheral estrogen; estradiol levels should be tracked
- •Semen analysis: For fertility research contexts; spermatogenesis parameters at baseline and endpoint
- •Complete metabolic panel: Hepatic metabolism; LFTs are standard
- •Ophthalmologic screening: SERMs can cause visual disturbances; baseline eye exam is standard for long-term protocols
Comparison: Enclomiphene vs. Other HPG Axis Modulators
| Agent | Class | HPG Effect | Key Advantage | Key Limitation |
|---|---|---|---|---|
| Enclomiphene | SERM (trans-isomer) | Stimulates LH/FSH/T | No accumulation; clean PK | Not broadly FDA-approved |
| Clomiphene citrate | SERM (racemic) | Stimulates LH/FSH/T | FDA-approved (ovulation) | Zuclomiphene accumulates |
| Tamoxifen | SERM | Stimulates LH/FSH/T | FDA-approved (breast cancer) | Less potent HPG stimulation |
| HCG | Gonadotropin | Directly stimulates testes | Bypasses HPG axis | Does not stimulate FSH |
| Gonadorelin/GnRH | GNRH | Stimulates pituitary | Most physiological | Requires pulsatile delivery |
Key Published Literature
1. Kim ED, et al. "Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone." Fertility and Sterility, 2013.
2. Wiehle RD, et al. "Enclomiphene citrate is a selective estrogen receptor antagonist that is not clomiphene: implications for men with secondary hypogonadism." The Aging Male, 2012.
3. Hill S, et al. "Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men." IDrugs, 2009.
Conclusion
Enclomiphene represents the pharmacologically refined evolution of clomiphene citrate for HPG axis research. By isolating the active trans-isomer from the long-accumulating zuclomiphene cis-isomer, enclomiphene provides a cleaner pharmacokinetic profile for studying hypothalamic estrogen receptor antagonism, gonadotropin dynamics, and endogenous testosterone restoration. Its clinical development history — including Phase III data for secondary hypogonadism and comparison with testosterone gel — provides a robust evidence base for research protocol design. For fertility research, HPG axis restoration models, and SERM mechanism studies, enclomiphene is among the most well-characterized tools available.
For research purposes only. Consult a licensed healthcare professional for any therapeutic needs.
---
This article is for educational and research purposes only. Peptides.SO does not endorse or encourage the use of research compounds outside of properly supervised clinical contexts.